Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis
- PMID: 12085034
- DOI: 10.1067/mge.2002.125367
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis
Abstract
Background: Published data on the risk of colorectal neoplasia in patients with ulcerative colitis with and without primary sclerosing cholangitis are conflicting. A meta-analysis was performed to synthesize available publications and to compare the risk of colorectal neoplasia in patients with ulcerative colitis with and without primary sclerosing cholangitis.
Methods: By using MEDLINE and manual search methods, studies were identified that compared the risk of colorectal neoplasia (dysplasia and carcinoma) in patients with ulcerative colitis with and without primary sclerosing cholangitis. In addition, citations were reviewed in relevant articles and proceedings from gastroenterology meetings, and investigators were contacted when data were incomplete. The summary odds ratio (OR) was then calculated for the risk for patients with ulcerative colitis and primary sclerosing cholangitis of having colorectal neoplasia develop compared with that of patients with ulcerative colitis without primary sclerosing cholangitis.
Results: Eleven studies met all eligibility criteria for the meta-analysis. Patients with ulcerative colitis and primary sclerosing cholangitis are at increased risk of colorectal dysplasia and carcinoma compared with patients with ulcerative colitis alone; OR 4.79: 95% CI [3.58, 6.41] with the Mantel-Haenszel method, and OR 5.11: 95% CI [3.15, 8.29] with the Der Simonian and Laird method. This increased risk is present even when the risk of colorectal carcinoma alone is considered; OR 4.09: 95% CI [2.89, 5.76] and OR 4.26: 95% CI [2.80, 6.48] by using, respectively, the Mantel-Haenszel and the Der Simonian and Laird methods.
Conclusions: Patients with ulcerative colitis and primary sclerosing cholangitis have a significantly higher risk for the development of colorectal neoplasia than patients with ulcerative colitis but not primary sclerosing cholangitis. More intensive colonoscopic surveillance should be considered for patients with ulcerative colitis and primary sclerosing cholangitis.
Similar articles
-
Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Dis Colon Rectum. 1995 Jan;38(1):37-41. doi: 10.1007/BF02053855. Dis Colon Rectum. 1995. PMID: 7813342
-
Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.Dis Colon Rectum. 2001 Jan;44(1):77-85. doi: 10.1007/BF02234825. Dis Colon Rectum. 2001. PMID: 11805567
-
Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma.Int J Colorectal Dis. 2000 Jun;15(3):167-71. doi: 10.1007/s003840000223. Int J Colorectal Dis. 2000. PMID: 10954188
-
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.Eur J Gastroenterol Hepatol. 2016 Apr;28(4):383-90. doi: 10.1097/MEG.0000000000000576. Eur J Gastroenterol Hepatol. 2016. PMID: 26938805 Review.
-
Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?Gut. 2001 Mar;48(3):430-4. doi: 10.1136/gut.48.3.430. Gut. 2001. PMID: 11171838 Free PMC article. Review. No abstract available.
Cited by
-
Managing risks of neoplasia in inflammatory bowel disease.Curr Gastroenterol Rep. 2012 Apr;14(2):174-80. doi: 10.1007/s11894-012-0247-7. Curr Gastroenterol Rep. 2012. PMID: 22359106 Review.
-
Surveillance programmes for neoplasia in colitis.J Gastroenterol. 2011 Jan;46 Suppl 1:1-5. doi: 10.1007/s00535-010-0309-2. Epub 2010 Aug 27. J Gastroenterol. 2011. PMID: 20798970
-
Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget.World J Gastrointest Endosc. 2022 Feb 16;14(2):85-95. doi: 10.4253/wjge.v14.i2.85. World J Gastrointest Endosc. 2022. PMID: 35316980 Free PMC article. Review.
-
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease.Intest Res. 2023 Oct;21(4):420-432. doi: 10.5217/ir.2023.00039. Epub 2023 Sep 1. Intest Res. 2023. PMID: 37519211 Free PMC article. Review.
-
Risk of Hepatobiliary-Gastrointestinal Malignancies and Appropriate Cancer Surveillance in Patients With Primary Sclerosing Cholangitis.Cureus. 2021 Nov 26;13(11):e19922. doi: 10.7759/cureus.19922. eCollection 2021 Nov. Cureus. 2021. PMID: 34976523 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous